Bird’s eye view: Similar But Equal? Nearly Half of States Considering ‘Biologics’ Bills

Posted on 04-09-2015 by
Tags: Trending News & Topics , Affordable Care Act , Obama Care , trending news

The below article is an excerpt courtesy State Net® Capitol Journal, written by Rich Ehisen.

The ACA created an “abbreviated licensure pathway” for biologic biosimilar medications becoming available on the drug market. States have since been considering bills that address that eventuality. In January, the FDA approved the first such biosimilar. But while the idea is that biosimilars will be used much like generic molecular drugs to drive down the cost of those medications, biosimilars are very different and present different regulatory issues for lawmakers.

In fact, according to a recent State Net Capitol Journal article, Nearly Half of States Considering 'Biologics' Bills, 22 states have filed or introduced bills or resolutions this session related to “biologics” or “biosimilars,” medical drugs generally derived from living cells. Three of the bills have been signed into law – Utah Utah’s HB 279, Virginia’s HB 1750 and Wyoming’s SB 3 – and a non-binding resolution – GEORGIA’s HR 34 – has been adopted. And bills have been sent to the governor in Colorado and Georgia.

While biosimilar medication is here, what it means for patients, insurers, doctors, pharmacists, drug manufacturers and state lawmakers is still far from determined.

If you would like to receive more information similar to the above, sign up for the StateNet Capitol Journal Newsletter.

The above article and image are courtesy of StateNet Capitol Journal.

Your comment has been posted.   Close
Thank you, your comment requires moderation so it may take a while to appear.   Close